1. Home
  2. Health
  3. Health Topics A-Z

Scleroderma

Description

An in-depth report on the causes, diagnosis, treatment, and prevention of scleroderma.

Alternative Names

Systemic Sclerosis

Treatment for Skin Thickening

Nitroglycerin is a rapidly acting nitrate and is used as an ointment (Nitro-Bid, Nitrol, Nitrong, Nitrostat) to treat hardened skin. Before applying it, any ointment that remains from the previous application should be removed.

Phototherapy

UVA-1 Phototherapy. Phototherapy (light therapy), specifically an approach called ultraviolet A-1 (UVA-1) radiation, is now considered the treatment of choice for local scleroderma by some experts. This treatment produces long UVA wave lengths that do not promote sunburn and may actually repair DNA in damaged skin cells. Research suggests that UVA-1 therapy blocks inflammatory immune factors and the process leading to overproliferation of collagen, addressing the underlying mechanisms of scleroderma. The procedure is effective for all stages of morphea and increases skin elasticity and, and in some cases, achieves complete clearance of symptoms. In one small study, patients with localized scleroderma received 30 treatments over a period of 12 weeks. In a majority of the patients, 80% of the skin patches disappeared or significantly improved. There were no side effects.

UVA-1 phototherapy is quite expensive and requires a special light source not readily available everywhere. In addition, studies are reporting an increased risk with UVA radiation. Whether this applies to UVA-1 phototherapy is not yet clear. Nonetheless, phototherapy is still an effective and important treatment of scleroderma. It may prove to be even more beneficial when combined with certain medications, such as calcipotriene (Dovonex) a form of vitamin D3.

PUVA. An alternative phototherapy regimen called PUVA uses oral drugs known as psoralens before UVA treatment. It has been used for other skin diseases, including psoriasis. It may prove to be useful for patients with early-onset diffuse scleroderma. In one study, most of those treated with PUVA for two days a month for up to eight years experienced improvement or stabilization in nearly all scleroderma symptoms. Tests for kidney function remained normal. This treatment is known to increase the risk for skin cancer.

Phototherapy with Psoralen Water Bath. Yet another procedure uses UVA light therapy after patients take a bath containing a solution of the psoralen 8-methoxypsoralen (8-MOP). It is safe and well tolerated although benefits appear to be minor and occur only in a small subset of patients.

Extracorporeal Photopheresis. Another phototherapy treatment under investigation is called extracorporeal photopheresis. It involves withdrawing the patients blood and treating it with ultraviolet light. Little data exists on its effectiveness and experts do not recommend it at this time. Still, some experts argue that some initial promise in its use warrants more research.

Vitamin D3 Analogs

A form of vitamin D3, calcipotriene (Dovonex), also called calcipotriol in Europe, appears to help block skin cell proliferation. It also has anti-inflammatory properties and is being investigated as an oral and topical treatment for local scleroderma. It may be prove to be beneficial when combined with low-dose ultraviolet A1 phototherapy.

Immunosuppressive Agents

D-penicillamine is proving to be an effective agent for softening skin and reducing thickness. (Improvements in thickness with this drug have also been associated with improved survival.)

Methotrexate (Rheumatrex) is another agent commonly used may be even more effective than penicillamine.

Oral corticosteroids, such as prednisolone and prednisone, are also often employed.

adam.com
Explore Health Topics A-Z
About.com Special Features

Learn how you can reduce your your numbers with these nutrition and exercise tips. More >

Keep yourself, and your family, happy and healthy this fall with these tips. More >

  1. Home
  2. Health
  3. Health Topics A-Z

©2009 About.com, a part of The New York Times Company.

All rights reserved.